PT3185867T - Processo de cristalização de derivados de aripiprazol em formulações de libertação prolongada para tratamento de esquizofrenia - Google Patents
Processo de cristalização de derivados de aripiprazol em formulações de libertação prolongada para tratamento de esquizofreniaInfo
- Publication number
- PT3185867T PT3185867T PT158364315T PT15836431T PT3185867T PT 3185867 T PT3185867 T PT 3185867T PT 158364315 T PT158364315 T PT 158364315T PT 15836431 T PT15836431 T PT 15836431T PT 3185867 T PT3185867 T PT 3185867T
- Authority
- PT
- Portugal
- Prior art keywords
- schizophrenia
- treatment
- extended release
- release formulations
- crystallization process
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical class ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title 1
- 238000002425 crystallisation Methods 0.000 title 1
- 230000008025 crystallization Effects 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041341P | 2014-08-25 | 2014-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3185867T true PT3185867T (pt) | 2021-04-12 |
Family
ID=55347322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158364315T PT3185867T (pt) | 2014-08-25 | 2015-08-24 | Processo de cristalização de derivados de aripiprazol em formulações de libertação prolongada para tratamento de esquizofrenia |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10064859B2 (enExample) |
| EP (2) | EP3185867B1 (enExample) |
| JP (2) | JP6591546B2 (enExample) |
| CN (2) | CN111454207B (enExample) |
| AU (2) | AU2015306910B2 (enExample) |
| CA (1) | CA2959329C (enExample) |
| CY (1) | CY1124058T1 (enExample) |
| DK (1) | DK3185867T3 (enExample) |
| ES (2) | ES2994850T3 (enExample) |
| HR (1) | HRP20210551T1 (enExample) |
| HU (1) | HUE054641T2 (enExample) |
| IL (1) | IL250661B (enExample) |
| LT (1) | LT3185867T (enExample) |
| MA (2) | MA55917A (enExample) |
| PL (1) | PL3185867T3 (enExample) |
| PT (1) | PT3185867T (enExample) |
| RS (1) | RS61709B1 (enExample) |
| SI (1) | SI3185867T1 (enExample) |
| SM (1) | SMT202100212T1 (enExample) |
| WO (1) | WO2016032950A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| SMT202100481T1 (it) | 2014-08-18 | 2021-09-14 | Alkermes Pharma Ireland Ltd | Composizioni per profarmaci di aripiprazolo |
| SMT202100212T1 (it) * | 2014-08-25 | 2021-07-12 | Alkermes Pharma Ireland Ltd | Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia |
| WO2016181406A1 (en) * | 2015-05-08 | 2016-11-17 | Davuluri Ramamohan Rao | Improved process for the preparation of aripiprazole with reduced particle size |
| WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
| ES2903278T3 (es) | 2017-07-28 | 2022-03-31 | Interquim Sa | Procedimiento para la preparación de aripiprazol lauroxil |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN113105389B (zh) * | 2021-04-16 | 2022-04-08 | 江苏海洋大学 | 一种阿立哌唑药物共晶及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| BRPI0415531B8 (pt) * | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| CA2655335C (en) | 2007-12-19 | 2016-09-06 | Janssen Pharmaceutica N.V. | Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same |
| US20110003823A1 (en) | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
| PT2445502T (pt) | 2009-06-25 | 2017-09-22 | Alkermes Pharma Ireland Ltd | Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos |
| WO2012077134A1 (en) * | 2010-12-07 | 2012-06-14 | Ind-Swift Laboratories Limted | Process for preparing aripiprazole polymorphs |
| AU2012204174B2 (en) * | 2011-01-07 | 2016-07-21 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| JP6654042B2 (ja) * | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| SMT202100212T1 (it) * | 2014-08-25 | 2021-07-12 | Alkermes Pharma Ireland Ltd | Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia |
-
2015
- 2015-08-24 SM SM20210212T patent/SMT202100212T1/it unknown
- 2015-08-24 WO PCT/US2015/046525 patent/WO2016032950A1/en not_active Ceased
- 2015-08-24 RS RS20210433A patent/RS61709B1/sr unknown
- 2015-08-24 LT LTEP15836431.5T patent/LT3185867T/lt unknown
- 2015-08-24 PL PL15836431T patent/PL3185867T3/pl unknown
- 2015-08-24 HR HRP20210551TT patent/HRP20210551T1/hr unknown
- 2015-08-24 ES ES21150116T patent/ES2994850T3/es active Active
- 2015-08-24 EP EP15836431.5A patent/EP3185867B1/en active Active
- 2015-08-24 SI SI201531576T patent/SI3185867T1/sl unknown
- 2015-08-24 MA MA055917A patent/MA55917A/fr unknown
- 2015-08-24 CN CN202010375290.3A patent/CN111454207B/zh active Active
- 2015-08-24 AU AU2015306910A patent/AU2015306910B2/en active Active
- 2015-08-24 US US14/833,638 patent/US10064859B2/en active Active
- 2015-08-24 JP JP2017530956A patent/JP6591546B2/ja active Active
- 2015-08-24 ES ES15836431T patent/ES2862098T3/es active Active
- 2015-08-24 CN CN201580057857.XA patent/CN107106556B/zh active Active
- 2015-08-24 MA MA40480A patent/MA40480B1/fr unknown
- 2015-08-24 PT PT158364315T patent/PT3185867T/pt unknown
- 2015-08-24 DK DK15836431.5T patent/DK3185867T3/da active
- 2015-08-24 HU HUE15836431A patent/HUE054641T2/hu unknown
- 2015-08-24 CA CA2959329A patent/CA2959329C/en active Active
- 2015-08-24 EP EP21150116.8A patent/EP3865476B1/en active Active
-
2017
- 2017-02-19 IL IL250661A patent/IL250661B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,721 patent/US10478434B2/en active Active
-
2019
- 2019-09-18 JP JP2019169473A patent/JP2019210296A/ja active Pending
- 2019-10-08 US US16/595,608 patent/US10973816B2/en active Active
-
2020
- 2020-11-04 AU AU2020264303A patent/AU2020264303B2/en active Active
-
2021
- 2021-03-24 US US17/211,352 patent/US11883394B2/en active Active
- 2021-04-13 CY CY20211100318T patent/CY1124058T1/el unknown
-
2023
- 2023-12-18 US US18/543,767 patent/US20240245676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250661A0 (en) | Crystallization process of antecedents of aripiprazole in sustained-release formulations for the treatment of schizophrenia | |
| PT3169328T (pt) | Derivados de quinolina para o tratamento de doenças inflamatórias | |
| IL246954B (en) | A medical preparation containing a senolytic factor for the treatment of osteoarthritic joints | |
| SI3097085T1 (sl) | Derivati benzoksazinona za zdravljenje kožnih bolezni | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| SI3210973T1 (sl) | Heteroarilne spojine za zdravljenje oftalmičnih bolezni | |
| IL256127B (en) | Use of benzimidazole history for nocturnal acid reflux | |
| IL246721B (en) | History of 5-benzylisoquinoline for the treatment of cardiovascular diseases | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| IL249989B (en) | Spiritual preparations containing ciclomiphene for use in the method of treating hot flashes | |
| PL3142641T3 (pl) | Preparaty do leczenia nadczynności tarczycy | |
| EP3100734A4 (en) | Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma | |
| IL248568A0 (en) | A process for the preparation of dihydroisoxazole derivatives | |
| IL249463A0 (en) | Production method for (s)-2-acetyloxypropionic acid and their derivatives | |
| PL3223799T3 (pl) | Sposób otrzymywania kompozycji składnik farmaceutyczny-polimer | |
| PT3143032T (pt) | Novos derivados terapêuticos de oxazafosforinas e as suas utilizações terapêuticas | |
| HUP1400545A2 (hu) | Eljárás benzazepin származékok elõállítására | |
| MA40446A (fr) | Procédé de préparation de formulations pour inhalation | |
| HUP1400518A2 (hu) | Eljárás tofacitinib elõállítására | |
| PL3331517T3 (pl) | Zastosowanie hydroksymocznika w celu zapobiegania brakowi perfuzji w siatkówce | |
| GB201418268D0 (en) | Composition & methods of treatment | |
| GB201418272D0 (en) | Composition & methods of treatment |